Paragon 28 Reports Preliminary Revenue Growth for 2024
Paragon 28, Inc. (NYSE: FNA), a prominent player in the medical device industry, has announced its preliminary unaudited revenue figures for the fourth quarter and the entire fiscal year ending in 2024. With its focus solely on the foot and ankle orthopedic market, Paragon 28 continues to demonstrate impressive growth and innovation throughout its operations.
Impressive Revenue Figures
The company anticipates its net revenue for the fourth quarter of 2024 will fall within the range of $71.5 million to $71.8 million. This represents a notable growth rate of approximately 18.0% to 18.5% compared to the same period in 2023. Additionally, for the full fiscal year of 2024, Paragon 28 expects its revenues to be between $255.9 million and $256.2 million, reflecting an increase of about 18.2% to 18.4% from the previous year.
Commitment to Transparency
While the reported figures are promising, it's essential to understand that these numbers are preliminary and subject to adjustments pending the completion of quarterly and year-end closing procedures. Paragon 28 has stated that its independent registered public accounting firm has not yet audited this preliminary financial data. As a result, the actual outcomes may differ when the final results are compiled and reviewed.
Company's Future Outlook
Albert DaCosta, Chairman and CEO of Paragon 28, shared his enthusiasm regarding the company's trajectory. "2024 has been a transformative year for Paragon 28, marked by significant achievements in growth, innovation, and operational efficiency. Our sustained efforts have yielded results that position us for continued profitability and success moving forward," he stated. Looking towards 2025, DaCosta is eager to maintain this momentum, aiming to redefine possibilities within the foot and ankle market.
About Paragon 28, Inc.
Paragon 28 is headquartered in Englewood, Colorado, and remains dedicated to enhancing patient outcomes with its innovative orthopedic solutions tailored for the foot and ankle. With a commitment to addressing various foot and ankle conditions—such as fracture fixation, Charcot foot, and progressive collapsing foot deformity—Paragon 28 aims to simplify surgical procedures and improve recovery rates for patients.
Commitment to Innovation and Growth
The company prides itself on designing products that cater to both patients and healthcare professionals, intending to reduce complication rates associated with surgical procedures. Paragon 28's focus on research and product development ensures that it remains at the forefront of the orthopedic market, continually offering the latest advancements to improve surgical outcomes and patient satisfaction.
Frequently Asked Questions
What is Paragon 28, Inc. known for?
Paragon 28 is recognized for its innovative medical devices specializing in the foot and ankle orthopedic sector.
What are the preliminary revenue estimates for Paragon 28 in 2024?
Paragon 28 expects its preliminary net revenue for the fourth quarter to be between $71.5 million and $71.8 million, and for the full year, between $255.9 million and $256.2 million.
How does Paragon 28 ensure the accuracy of its financial reporting?
The company emphasizes the preliminary nature of their financial estimates, highlighting that final results may vary pending completion of financial audits and reviews.
Who is the CEO of Paragon 28?
Albert DaCosta serves as the Chairman and CEO of Paragon 28, Inc.
What goals does Paragon 28 have for the future?
They aim to build on their achievements in growth and innovation to ensure sustainable profitability and redefine the orthopedic market for foot and ankle care.
